2021CSCO: Current and prospects of precision radiotherapy combined with immunotherapy for lung cancer

The National Conference on Clinical Oncology, also known as the CSCO Academic Annual Conference, is hosted by the Chinese Society of Clinical Oncology (CSCO) and other units
.

The 24th National Conference on Clinical Oncology, the 2021 CSCO Academic Annual Conference, will be held in the form of an online conference from the 25th to the 29th of this month

The status of the CSCO annual meeting in the Chinese tumor treatment community is just like ESMO for Europe, ASCO and AACR for the United States, it is a grand event gathering the most cutting-edge research progress each year
.

I believe that many doctors and patients are paying attention to this event, and expect that these cutting-edge advances can push the level of cancer treatment to a new level

ASCO

On September 27th, Professor Hui Zhouguang from the Cancer Hospital of the Chinese Academy of Medical Sciences gavean online academic reportentitled " Precise Radiotherapy and Immunotherapy for Lung Cancer ".
Professor Hui Zhouguang studied the mechanism and clinical progress of radiotherapy and immunotherapy.
The three aspects of , problems and challenges were interpreted in detail
.

September 27, September 27, professor of Chinese Academy of Medical Sciences Cancer Hospital, Hui Zhou Chinese Academy of Medical Sciences Cancer Hospital, Hui Zhou, Professor light lung precision radiotherapy immune therapy now with the prospect of lung cancer precision radiotherapy immune therapy now with the prospect of precise immune Interpretation of the mechanism, clinical progress, problems and challenges of radiotherapy and immunotherapy The mechanism, clinical progress, problems and challenges of radiotherapy and immunotherapy

Radiotherapy combined with immunotherapy is one of the current research hotspots.
In the past year alone, nearly 80 radiotherapy + immunotherapy clinical studies have been carried out in the field of lung cancer, and the clinical enthusiasm is not diminishing, and the number of studies is still rising
.

The mechanism of action of radiotherapy + immunotherapy lies in the synergy of the two.
Radiotherapy can expose tumor antigens, produce in situ vaccines, promote a series of tumor antigen presentation, reverse the immunosuppressive factors in the immune microenvironment, and have a synergistic promotion for immunotherapy Role
.

Progress in radiotherapy combined with immunotherapy for lung cancer

Progress in radiotherapy combined with immunotherapy for lung cancer

A phase II KEYNOTE-799 study evaluated the safety and efficacy of pembrolizumab combined with concurrent radiotherapy and chemotherapy in the treatment of stage III unresectable NSCLC
.

The study is divided into cohort A (squamous cell carcinoma + non-squamous cell carcinoma) and cohort B (non-squamous cell carcinoma only).

NSCLC , pembrolizumab combined with concurrent radiotherapy and chemotherapy have good efficacy, and the efficacy is not related to PD-L1 and pathological types, and the toxicity is in line with expectations

Early trials Peng Broken natalizumab in combination with chemotherapy showed that in patients with unresectable stage III non-small cell lung cancer, all showed acceptable tolerability and promising progression-free survival (PFS) Peng burro beads Early trials of monoclonal antibodies combined with chemotherapy have shown that in patients with unresectable stage III non-small cell lung cancer, they all show acceptable tolerability and promising progression-free survival (PFS)

There is also a phase III clinical study called EA5181 that is evaluating the efficacy and safety of simultaneous dovalizumab combined with concurrent radiotherapy and chemotherapy compared with the standard PACIFIC model in the treatment of stage III unresectable NSCLC
.

90 patients have been enrolled .

Radiotherapy combined with immunotherapy faces many challenges, mainly because radiotherapy combined with immunotherapy needs to overcome many influencing factors
.

In the process of combined immunotherapy, radiotherapy technology, radiotherapy dose, division method, irradiation site, radiotherapy volume, immunotherapy intervention point, immune drug selection, disease/patient and other issues require more sufficient clinical trial data to demonstrate.

Reference materials:

1.